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Abstract
Background:  The positive transcription elongation factor b (P-TEFb) composed by CDK9/
CyclinT1 subunits is a dedicated co-factor of HIV transcriptional transactivator Tat protein.
Transcription driven by the long terminal repeat (LTR) of HIV involves formation of a quaternary
complex between P-TEFb, Tat and the TAR element. This recruitment is necessary to enhance the
processivity of RNA Pol II from the HIV-1 5' LTR promoter. The activity of P-TEFb is regulated in
vivo and in vitro by the HEXIM1/7SK snRNA ribonucleic-protein complex.
Results: Here we report that Tat transactivation is effectively inhibited by co-expression of
HEXIM1 or its paralog HEXIM2. HEXIM1 expression specifically represses transcription mediated
by the direct activation of P-TEFb through artificial recruitment of GAL4-CycT1. Using appropriate
HEXIM1 mutants we determined that effective Tat-inhibition entails the 7SK snRNA basic
recognition motif as well as the C-terminus region required for interaction with cyclin T1.
Enhanced expression of HEXIM1 protein modestly affects P-TEFb activity, suggesting that HEXIM1-
mediated repression of Tat activity is not due to a global inhibition of cellular transcription.
Conclusion: These results point to a pivotal role of P-TEFb for Tat's optimal transcription activity
and suggest that cellular proteins that regulate P-TEFb activity might exert profound effects on Tat
function in vivo.
Background
The positive transcription elongation factor b (P-TEFb)
composed by CDK9/CyclinT1, has emerged as a signifi-
cant co-factor of the HIV Tat protein. P-TEFb complex has
been shown to associate with and phosphorylate the car-
boxyl-terminal domain (CTD) of RNA pol II, thereby
enhancing elongation of transcription [1-3]. Tat protein
binds an uracil containing bulge within the stem-loop sec-
ondary structure of the Tat-activated region (TAR-RNA) in
HIV-1 transcripts [4-6]. Tat functions as an elongation fac-
tor and stabilizes the synthesis of full-length viral mRNAs
by preventing premature termination by the TAR-RNA
stem-loop. Physical and functional interactions between
Tat and P-TEFb have been well documented [7,8]. Tat
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binds to P-TEFb by direct interaction with the human
cyclinT1, and the critical residues required for interaction
have been delineated [9,10]. The current model for
recruitment of P-TEFb to the LTR, predicts the formation
of the Tat-P-TEFb complex, which efficiently binds TAR,
allowing CDK9 to phosphorylate the CTD of RNAPII,
thereby, enhances processivity of the polymerase to pro-
duce full-length mRNAs [3,7-10].
Like other CDKs, the P-TEFb activity is regulated by a ded-
icated inhibitor. Two different P-TEFb complexes exist in
vivo [11,12]. The active complex is composed of two sub-
units, the CDK9 and its regulatory partners cyclinT1 or T2.
In addition, a larger inactive complex has been identified,
which comprises of four subunits, CDK9, cyclinT1 or T2,
the abundant small nuclear RNA 7SK and the HEXIM1
protein [13-17]. It has been recently shown that HEXIM1
has the inherent ability to associate with cyclin T1 and
binding of 7SK snRNA turns the HEXIM1 into a P-TEFb
inhibitor [15-17]. The relative presence of core and inac-
tive P-TEFb complexes changes rapidly in vivo [11,12].
Several stress-inducing agents trigger dissociation of the
inactive P-TEFb complex and subsequent accumulation of
kinase active P-TEFb [11]. Thus, the 7SK-HEXIM1 ribonu-
cleic complex represents a new type of CDK inhibitor that
contributes to regulation of gene transcription. A further
level of complexity of this system comes from the recent
identification of HEXIM2, a HEXIM1 paralog, which reg-
ulates P-TEFb similarly as HEXIM1 through association
with 7SK RNA [18,19].
It has been showed that Tat binds exclusively to the active
P-TEFb complex [13]. Thus the presence of HEXIM1/7SK
snRNA in P-TEFb complexes prevents Tat binding. Since
the association between 7SK RNA/HEXIM1 and P-TEFb
appears to compete with binding of Tat to cyclinT1, we
have speculated that the TAR RNA/Tat system may com-
pete with the cellular 7SK snRNA/HEXIM1 system in the
recruitment of the active P-TEFb complex [13]. Accord-
ingly, it has been shown that over-expression of HEXIM1
represses Tat function [14,17].
We show here that HEXIM1, or its paralog HEXIM2,
inhibits Tat trans-activation of HIV-LTR driven gene
expression, and more importantly, we demonstrated the
role of the 7SK snRNA recognition motif as well as the
binding to cyclin T1 as crucial elements for efficient Tat
inhibition.
Results
Tat activity is inhibited by HEXIM1
Tat activity involves direct interaction with CDK9/
CyclinT1 (P-TEFb) complex. However, two major P-TEFb-
containing complexes exits in human cells [11,12]. One is
active and restricted to CDK9 and cyclin T, the other is
inactive and it contains HEXIM1 or 2 and 7SK snRNA in
addition to P-TEFb [15,17]. We have previously shown
that Tat interacts only with the active P-TEFb complex
[13]. Because the two complexes are in rapid exchange, we
sought to determine the functional consequences of the
over-expression of HEXIM1 and 7SK snRNA on HIV-1
LTR-driven gene transcription. To this end we performed
transient transfections in human 293 cells using the HIV-
LTR-Luc reporter in the presence of increasing amounts of
Flag-taggeted HEXIM1 and 7SK snRNA, respectively.
Dose-dependent expression of F:HEXIM1 was monitored
by immunoblotting with anti-HEXIM1 antibody (Fig. 1
panel A). As presented in Fig. 1B, we found that basal tran-
scription from the LTR sequences was unaffected by the
presence of F:HEXIM1 or 7SK RNA. In contrast, Tat-medi-
ated transactivation of the HIV-1 LTR was inhibited by the
over-expression of F:HEXIM1 in a dose-dependent man-
ner. Ectopic expression of 7SK RNA did not significantly
affected HIV-LTR-Luc expression either alone or in combi-
nation with F:HEXIM1. Thus, it appears that HEXIM1 is
able to repress Tat-mediated activation. To further sub-
stantiate the inhibitory function of HEXIM1 we sought to
extend our analysis using the murine CHO cells. Tat pro-
tein is a potent activator of HIV-1 LTR transcription in pri-
mate cells but only poorly functional in rodent cells [6,7].
However, Tat-mediated activation can be rescued by
enforced expression of human cyclin T1 [6,7]. As pre-
sented in Fig. 1C we found that, while hCycT1 rescued Tat
function, ectopic expression of HEXIM1 effectively inhib-
its Tat activity. Most importantly, Tat enhancement medi-
ated by hCycT1 was effectively abrogated by co-expression
of HEXIM1 in a dose-dependent manner. Finally, like in
human cells, ectopic expression of 7SK snRNA did not
have any significant effect on Tat activity.
The results reported above suggested that ectopic expres-
sion of HEXIM1 inhibits Tat activity. A large number of
evidences indicate that Tat-transactivation is mainly due
to the recruitment of the cellular complex P-TEFb to the
LTR, causing phosphorylation of the RNAPII CTD [1,6-
10]. Accordingly, we and others have previously showed
that artificial recruitment of P-TEFb to the HIV-1 pro-
moter is sufficient to activate the HIV-1 promoter in the
absence of Tat [20,21]. We sought to determine the conse-
quences of ectopically expressed F:HEXIM1 on P-TEFb
induced transcription in the absence of Tat. We showed
that direct recruitment of CyclinT1 to a promoter template
by fusion to the GAL4 DNA binding domain, activates
transcription from an HIV-1 LTR (G5HIV-Luc) reporter
bearing GAL4 sites [20]. Human 293 cells were transfected
with the G5HIV-Luc reporter along with GAL4-fusion
expression vectors in the presence of F:HEXIM1. As shown
in Fig. 2A, we found that GAL4-CycT1 effectively activates
transcription from the HIV-1 LTR reporter, and co-expres-
sion of F:HEXIM1 resulted in a robust dose-dependentRetrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42
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inhibition. The specific effect of HEXIM1 expression was
highlighted by the results shown in Fig. 2B. G5HIV-Luc
reporter was activated by co-expression of a GAL4-TBP,
and such activation was largely unaffected by co-expres-
sion of HEXIM1. Thus, it appears that while HEXIM1
represses P-TEFb activity, enforced expression of this pro-
tein does not have significant effects on TBP-mediated
basal transcription.
Definition of the HEXIM1 regulatory domains involved in 
repression
To investigate the structural determinants of HEXIM1 pro-
tein in repression, the activity of Gal4-CycT1 on G5HIV-
Luc was monitored in the presence of co-transfected Flag-
tagged deletion mutants of HEXIM1. We found that
removal of the C-terminal amino acids affected the inhi-
bition as shown by the HEXIM1 (1–300) and (1–240)
mutants (Figure 3 lanes 6–8 and 9–11). In contrast,
removal of the 119 N-terminal amino acids of HEXIM1
(120–359) did not abolished inhibition (lanes 12–14).
However, further deletion of the N-terminal amino acids
(181–359) completely abolished the inhibitory effect
(lanes 15–17). Thus, HEXIM1-mediated repression
required the presence of the C-terminal domain (300–
359aa) as well as a central region between residues 120
and 181. Finally, we found that HEXIM2, which like
Overexpression of HEXIM1 protein represses Tat transactivation Figure 1
Overexpression of HEXIM1 protein represses Tat transactivation. Panel A, Increasing amounts (10, 100 and 500 ng) of Flag-
taggeted HEXIM1 were transfected into 293, cellular extracts were prepared at 48 hr after transfection and the relative levels 
on endogenous and exogenous HEXIM1 proteins were visualized by immunoblotting with anti-HEXIM1 antibody. Panel B, the 
HIV-Luc reporter (50 ng) was transfected into 293 cells in the presence of pSV-tat (50 ng) along with increasing (10, 100 and 
500 ng) amounts of F:HEXIM1 and 7SK RNA (10, 100 and 500 ng), as indicated. Panel C, HEXIM1 decreases the co-operative 
effect of CycT1 on Tat activation in rodent cells. Chinese hamster ovary cells (CHO) were transfected with the HIV-LTR-Luc 
reporter (50 ng) in the presence of pSV-Tat (100 ng), lane 1, and together with CMV-hCycT1 (200 ng), lane 2, in the presence 
of increasing amounts of F:HEXIM1 and 7SK RNA as in panel B. Each histogram bar represents the mean of at least three inde-
pendent transfections after normalization to Renilla luciferase activity to correct for transfection efficiency with the activity of 
the reporter without effect set to one. Standard deviations were less than 10%.
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HEXIM1, associates and inhibits P-TEFb activity, represses
Gal4-CycT1 activation in a dose dependent manner (lanes
18–20).
We have recently reported that the HEXIM1 C-terminal
domain (181–359) is involved in the binding to P-TEFb
through direct interaction with the cyclin-box of cyclinT1
[15], and the evolutionarily conserved motif (PYNT aa
202–205) is important for such interaction. The PYND
point mutant is impaired in repression and binding either
P-TEFb or 7SK RNA in vivo, albeit it retains the ability to
bind 7SK in vitro. In addition, we determined that
HEXIM1 binds 7SK snRNA directly and the RNA-recogni-
tion motif (KHRR) was identified in the central region of
the protein (aa 152–155). In fact, the HEXIM1-ILAA
mutant fails to interact in vivo and in vitro with 7SK
snRNA [15]. To test the importance of these motifs in
HEXIM1-mediated repression of Tat activity, HEXIM1
point mutants were co-transfected in 293 cells along with
Tat or Gal4-CycT1, respectively. As shown in Figure 4,
unlike wild-type HEXIM1, both mutants were unable to
repress Tat as well as Gal4-CycT activities, albeit they were
expressed at levels comparable to the wild-type protein.
Collectively, the results presented in figures 3 and 4
HEXIM1 represses GAL4-CycT1-mediated activation Figure 2
HEXIM1 represses GAL4-CycT1-mediated activation. Human 293 cells were transfected with 50 ng of G5-HIV Luc reporter 
DNA alone (lane 1) or in the presence of GAL4-expression plasmid DNA (200 ng), as indicated. The presence of the cotrans-
fected F:HEXIM1 (10, 100 and 500 ng) is indicated. Each histogram bar represents the mean of three independent transfections 
after normalization to Renilla luciferase activity. The results are presented as described in figure 1.
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HEXIM1 regulatory domains involved in repression Figure 3
HEXIM1 regulatory domains involved in repression. Human 293 cells were transfected with 50 ng of G5-HIV Luc reporter 
DNA alone (lane 1) or in the presence of 50 ng of pSV-Tat (lanes 2–20). The presence of increasing amounts (10, 100 and 500 
ng) F:HEXIM1 wild-type (lanes 3–5), various deletion mutants (lanes 6–17) and F:HEXIM2 wt(18–20) are indicated, respec-
tively. On the bottom, it is shown the western-blot of whole cells extracts from transfected cells probed with anti-Flag anti-
body from the indicated co-transfections. The results presented are from a single experiment after normalization to Renilla 
luciferase activity with the activity of the reporter without effect set to one. This experiment was performed three times with 
similar results.
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strongly suggest that HEXIM1-mediated inhibition of Tat
activity requires interaction with P-TEFb as well as bind-
ing to 7SK snRNA.
P-TEFb activity in the presence of enhanced expression of 
HEXIM1
Next we sought to determine whether enhanced expres-
sion of HEXIM1 might directly affect the P-TEFb activity.
293 cells were transfected with F:HEXIM1 and cellular
extracts from mock and transfected cells were prepared. P-
TEFb activity was assayed using as substrate the CTD4
peptide consisting of four consensus repeats of the
RNAPII CTD, and time-course kinase assays were per-
formed [15]. Briefly, P-TEFb and its associated factors
were affinity purified with anti-CycT1 antibody from
mock and F:HEXIM1 transfected cell extracts. Immuno-
precipitates were analyzed by immunoblotting for evalu-
ation of CDK9, cyclin T1 and HEXIM1 proteins,
respectively. The immunoprecipitates were then treated or
not treated with RNase A (Fig. 5). The RNase treatment
will degrade the 7SK snRNA thereby relieving the P-TEFb
inhibition by HEXIM1/7SK snRNP. In fact, samples
treated with RNase showed a robust increase in kinase
activity compared those not treated with RNase,
On top the relevant HEXIM1 functional domains are depicted Figure 4
On top the relevant HEXIM1 functional domains are depicted. Position of the point mutants ILAA and PYND are indicated. 
G5-HIVLuc reporter (50 ng) was transfected into 293 cells along with Gal4-CycT1 (200 ng) Panel A, or pSV-Tat (50 ng) panel 
B along with increasing amounts of Flag:HEXIM1 wilt type and mutants (10, 100 and 500 ng) as indicated. Each histogram bar 
represents the mean of three independent transfections after normalization to Renilla luciferase activity. The results are pre-
sented as described in figure 1. Panel C, western-blot with anti-HEXIM1 antibody demonstrated that the HEXIM1 effectors 
were expressed at comparable levels.
HEXIM1
Basic Domain Conserved domain
cyclinT1
152-KHRR-155
ILAA
202-PYNT-205
PYND
1 359
wt PYND ILAA
F:HEXIM1
HEXIM1
4
8
12
16
20
F
o
l
d
A
c
t
i
v
a
t
i
o
n
Gal4-CycT1 -++++ ++ + + + +
wt PYND ILAA
HEXIM1
1 2345 6 789 1 0 1 1
A
4
8
12
16
20
F
o
l
d
A
c
t
i
v
a
t
i
o
n
Tat
HEXIM1
++++ ++ + + + +
wt PYND ILAA
1 2 3 4 5 6 7 8 9 10 11
B
CRetrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42
Page 7 of 11
(page number not for citation purposes)
indicating that 7SK snRNA had been effectively degraded.
We found that the kinase activities of samples that were
treated with RNase were quantitatively the same in both
mock and F:HEXIM1 transfected extracts indicating equal
amounts total of P-TEFb in both samples. A modest, but
reproducible reduction of P-TEFb kinase activity (2-fold)
was observed in extracts from F-HEXIM1 transfected cells.
Altogether, these results demonstrated that over-expres-
sion of HEXIM1 resulted in a modest reduction of P-TEFb
activity, thus the inhibition of Tat activity is unlikely due
to a global reduction of cellular P-TEFb activity.
To further investigate the mechanism of inhibition of Tat-
mediated transcription by HEXIM1, we tested the relative
levels of transfected Tat protein in the presence of
F:HEXIM1. We found that ectopic expression of HEXIM1
did not affected Tat expression (Figure 6A). Next, we
sought to determine whether exogenous expression of
HEXIM1 might result in a decrease in Tat-bound CycT1.
To this end 293 cells were transfected with pSV-Tat in the
presence or absence of F-HEXIM1 using the same transfec-
tion conditions used in the Luciferase assays. Cells extracts
were immunoprecipitated with CycT1 antibody and the
P-TEFb activity in F:HEXIM1 transfected cells Figure 5
P-TEFb activity in F:HEXIM1 transfected cells. Human 293 cells were transfected with 100 ng of F:HEXIM1 and cell extracts 
were prepared from mock and F:HEXIM1 expressing cells at 48 hr after transfection. Cell extracts were immunoprecipitated 
with anti-cycT1 antisera. The relative amounts of immunopreicipitated cyclinT1, CDK9 and HEXIM1 were quantitated by 
immunoblotting. Samples were treated or not treated with RNase, as indicated. Kinase assays were performed using a CTD4 
peptide and 32P incorporation was quantified in arbitrary units and plotted versus time (min). This experiment was performed 
four times with similar results. A typical experiment is shown.
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immunoprecipitates were analyzed by immunoblotting
for evaluation of Tat, CycT1 and HEXIM1 proteins,
respectively. In two different experiments we found a
modest, but reproducible decrease in Tat-bound cyclin T1
(Fig. 6B). Thus, it appears that exogenous expression of
HEXIM1 results in a decrease of Tat-bound P-TEFb.
Discussion
Several lines of evidence have suggested that Tat function
is largely dependent upon the physical and functional
interaction with the cellular transcription factor P-TEFb.
The recruitment of P-TEFb to the LTR, involves the forma-
tion of the Tat-P-TEFb complex which efficiently binds
TAR, allowing CDK9 to phosphorylate the CTD of
RNAPII, thereby, enhances processivity of the polymerase
to produce full-length mRNAs [6-10]. Two different P-
Tat-CyclinT1 binding in the presence of HEXIM1 Figure 6
Tat-CyclinT1 binding in the presence of HEXIM1. Panel A. 293 cells were transfected with 50 ng of pSV-Tat in the presence or 
absence of F:HEXIM1 (100 ng) as indicated and at 48 hrs after transfection cell extracts were probe by Western blotting with 
anti-Tat. For accurate comparison increasing amounts of material (µl) were loaded on the gels. Panel B. 293 cells were trans-
fected as in Panel A, and cell extracts were immunoprecipitated with anti-CycT1. Immunocomplexes were analyzed on West-
ern blots as indicated. I, input, B; bound, FT; flow through. This experiment was performed two times with similar results.Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42
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TEFb complexes exist in vivo. The core active P-TEFb com-
prises two subunits, the catalytic CDK9 and a regulatory
partner cyclin T, and a larger inactive P-TEFb complex
comprised by CDK9, cyclin T, HEXIM1 protein and the
7SK snRNA [11-17]. The relative presence of core and
inactive P-TEFb complexes changes rapidly in vivo [11].
We have previously shown that the presence of HEXIM1/
7SK snRNA in P-TEFb complexes prevents Tat binding to
P-TEFb [13]. Since the association between 7SK RNA/
HEXIM1 and P-TEFb competes with binding of Tat to
cyclinT1, we have speculated that the TAR RNA/Tat system
may compete with the cellular 7SK snRNA/HEXIM1 sys-
tem [13]. Accordingly, it has been shown that over-expres-
sion of HEXIM1 represses Tat function [14,19] We show
here that HEXIM1 inhibits Tat function, while expression
of 7SK snRNA does not influence Tat activity. It is perti-
nent to note that 7SK RNA is an abundant snRNA [23],
and it is unlikely that 7SK might be rate-limiting for the
assembly of the inactive P-TEFb complex.
We have delineated important structural domains of
HEXIM1 required for repression of Tat. First, we found
that the C-terminal region is required for inhibition. Pre-
vious findings indicated that the C-terminal region of
HEXIM1 is involved in binding with cyclinT1 as well as
for homo and hetero-dimerization with HEXIM2
[15,18,19]. Second, point mutations in the evolutionarily
conserved motif PYNT (aa 202–205) abolished inhibi-
tion. It has recently shown a critical role of threonine 205
in P-TEFb binding [15]. Moreover, deletion mutants una-
ble to bind P-TEFb failed to repress Tat (Figure 3). There-
fore, it appears that HEXIM1 inhibition is strictly
dependent upon the integrity of the protein to interact
with P-TEFb. Third, a point mutant in the central part of
HEXIM1 (KHRR motif aa 152–155) strongly affects Tat
repression. Since this basic motif has been previously
shown as the 7SK snRNA recognition motif [15], we con-
clude that interaction between HEXIM1 and 7SK snRNA is
required for Tat repression. Collectively, these findings
strongly suggested that HEXIM1-mediated inhibition of
Tat required the formation of the P-TEFb/HEXIM1/7SK
complex.
We determined that enhanced expression of HEXIM1
resulted in a modest inhibition (2-fold) of P-TEFb activity
in vivo. Thus, HEXIM1-mediated inhibition of Tat activity
is unlikely due to a global inhibition of P-TEFb activity.
Moreover, we found that basal transcription from the LTR
sequences was largely unaffected by over-expression of
HEXIM1. Finally, ectopic expression of this protein does
not have significant effects on TBP-mediated basal
transcription. Thus, it appears that P-TEFb is specifically
required for Tat-dependent HIV LTR transcription. Our
results differ somewhat from those obtained in the Zhou
lab who found that exogenous expression of HEXIM1
affects both basal as well as Tat-induced transcription
[13]. These apparent discrepancies are possible due to dif-
ferent transfection conditions in which the relative
amounts of the over-expressed exogenous proteins are
likely different. We found that Tat expression which is
under the control of SV40 promoter remains largely unaf-
fected by co-expression of HEXIM. Our findings suggest a
dedicated role of P-TEFb in Tat activity. Recent studies
point to a specific role of P-TEFb for certain promoters. It
has recently found that P-TEFb is recruited to the IL-8 but
not to the IkBα  promoter [23], and it also represses tran-
scription of regulators such as the nuclear receptor
coactivator, PGC-1, in cardiac myocytes [24]. The specific
HEXIM-mediated inhibition of Tat activity underlines the
pivotal role of P-TEFb in the HIV LTR transcription.
The repression exerted by the HEXIM1 protein is likely the
results of a competition between Tat and HEXIM1 in
binding the P-TEFb. Since Tat binds only to the active P-
TEFb complex, it has been suggested that Tat might trap
the active form of P-TEFb as the PTEFb/7SK RNA/HEXIM1
complex appears to undergo continuous formation and
disruption  in vivo. In this scenario over expression of
HEXIM1 may counteract the binding of Tat to P-TEFb,
through a competitive association between the ectopic
expressed HEXIM1 and P-TEFb. Accordingly, we found
that exogenous expression of HEXIM1 results in a small
but detectable reduction in Tat-bound- P-TEFb. Our co-
immunoprecipitation results are consistent with recent
findings showing a mutually exclusive interaction of
HEXIM1 and Tat with cyclinT1 using recombinant puri-
fied proteins [25]. Because Tat and HEXIM1 interact with
the cyclin-box region of cyclinT1, it is plausible if not
likely, that the mutually exclusive interaction of these two
molecules with cyclinT1 is due to binding to the same
domain or to a sterical hindrance. However, these studies
have been performed in vitro in the absence of 7SK
snRNA.
The results reported here along with previous findings
strongly suggest the crucial role of 7SK in the interaction
between HEXIM1 and cyclinT1. In fact, HEXIM1 ILAA
mutant does not associate with 7SK in vivo and in vitro,
and co-immuprecipitation of cyclinT1 and 7SK RNA was
markedly reduced with ILAA mutant compared to wild
type [15]. Finally, as shown here ILAA mutant failed to
repress Tat activity, suggesting an important role of
HEXIM1/7SK interaction in Tat inhibition. Thus, associa-
tion between HEXIM1 and 7SK snRNA appears an impor-
tant determinant for Tat inhibition. Future in vitro and in
vivo interaction studies, in the presence of 7SK snRNA
may be instrumental to elucidate the role of 7SK/HEXIM1
complex in Tat activity.Retrovirology 2005, 2:42 http://www.retrovirology.com/content/2/1/42
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Conclusion
The studies described in this provides further support to
the pivotal role of P-TEFb for the optimal transcription Tat
activity and highlight the importance of the P-TEFb cellu-
lar co-factors HEXIM1/7SK snRNA complex in Tat activity.
Methods
Tissue culture and transfections
Human 293 and rodent CHO cells were grown at 37°C in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% fetal calf serum (Gibco, Life Technolo-
gies). Subconfluent cell cultures were transfected cell
cultures were transfected by a liposome method (Lipo-
fectAMINE reagent; Life Technologies, Inc.) in 2 cm/dish
in multiwells, using 100 ng of reporter DNA and different
amounts of activator plasmid DNA as indicated in the text
and 20 ng of Renilla luciferase expression plasmid (pRL-
CMV, Promega) for normalization of transfections effi-
ciencies. Cells were harvested 48 h after DNA transfec-
tions, and cellular extracts were assayed for luciferase
activity using Dual-Luciferase Reporter assay (Promega)
according to the manufacturer's instructions. The experi-
mental reporter luciferase activity was normalized to
transfection efficiency as measured by the activity deriving
from pRL-CMV.
Plasmids
The G5HIV-Luc contained the HIV-1 LTR sequences from
-83 to +82 of LTR driven the Luc gene with 5 GAL4 DNA-
binding sites inserted at -83. The pSV-Tat, GAL4-TBP,
GAL4-CycT1, have been described [20]. 7SK snRNA plas-
mid was kindly provided by S. Murphy [22]. All Flag-
taggeted HEXIM1 and HEXIM2 expression vectors were
constructed by insertion of the corresponding cDNA
regions into the EcoRV site of p3xFlag-CMV10 vector
(Clontech). Description of the deletion and point
HEXIM1 mutants have been described previously [15].
Full description of the expression vectors used in this
work is available upon request.
Western blotting and antibodies
Cells were lysed in ice-chilled buffer A (10 mM HEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 200 mM NaCl, 0.2 mM
EDTA), supplemented with 1 mM dithiothreitol, 40 U/ml
of RNasin (Promega), protease inhibitor cocktail (P-8340;
Sigma), and 0.5 % Nonidet P-40. Lysates were vortexed
and incubated for 20 min on ice and clarified by centrifu-
gations. Western blottings were performed using the fol-
lowing antibodies: the rabbit polyclonal anti-HEXIM1
(C4) has been previously described (6); anti-FLAG M2
Monoclonal Antibody (Sigma), goat polyclonal anti-
CycT1 (T-18), rabbit polyclonal anti-CDK9 (H-169) from
Santa Cruz, anti-Tat (NIH AIDS Research Reagent Pro-
gram). Binding was visualized by enhanced chemilumi-
nescence (ECL-plus Kit, Amersham Biosciences).
Co-immunoprecipitation and kinase assay
293 cells were transfected with pSV-Tat in the presence or
absence of F:HEXIM1 and cell extracts were prepared at 48
hrs after transfection. CycT1 was immunopurified from
cell extracts (1 mg) using anti-CycT1 (H-245) (sc-10750,
Santa Cruz). Input, immunoprecipited and flow through
materials were used in western blottings using anti-cycT1,
anti-HEXIM1 and anti-Tat, respectively. For kinase assays
293 cells were transfected with F:HEXIM1 and after 48 hr
P-TEFb complex was immunopurified from cell extracts (1
mg) using anti-CycT1 (H-245) (sc-10750, Santa Cruz) as
previously described [13,15]. Briefly, whole cell extracts
from mock and F:HEXIM1 transfected 293 cells were used
in immunoprecipitations together with 40µl of slurry
beads (protein G-Sepharose 4 Fast Flow, Amersham Bio-
sciences) pre-adsorbed with anti-CycT1 and the interac-
tions were carried out in buffer A for one hour at 4°C on
a wheel. After extensive washes one half of the immunop-
urified materials was used in western blotting to ensure
the presence of equal amounts of CDK9, HEXIM1 and
CycT1, respectively. The remaining material was sus-
pended and stirred at room temperature and split in two
equal aliquots. One of the aliquot was treated with 10U of
RNase A for 15 min at 30°C. Samples treated or not with
RNase were stirred at room temperature for three minutes
in 65 µl of buffer A containing [γ -32P]ATP (0,1 µCi/µl), 40
mM ATP, 0,1 µg/ml (YSPTSPS)4 peptide CTD4 (6, 8) and
RNasin (40 U/ml). Aliquots (20 µl) of the suspension
were mixed with SDS-PAGE loading buffer at intervals of
three minutes to stop the reaction. The phosphorylated
CTD4 substrate was separated on a 15% SDS-PAGE and
visualized by radiography. Incorporation of [32P] into
CTD peptide was quantified on a Bio-Rad
phosphoimager.
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